Published in final edited form as:

Mol Cancer Ther. 2010 May ; 9(5): 1111–1119. doi:10.1158/1535-7163.MCT-09-0833.

Driven to Death: Inhibition of Farnesylation Increases Ras Activity in Osteosarcoma and Promotes Growth Arrest and Cell Death

Mandy Geryk-Hall, Yanwen Yang, and Dennis P.M. Hughes

Department of Pediatrics Research, Children's Cancer Hospital, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030

Abstract

To improve cancer outcomes, investigators are turning increasingly to small molecule medicines that disrupt vital signaling cascades, inhibiting malignant growth or inducing apoptosis. One vital signaling molecule is Ras, and a key step in Ras activation is membrane anchoring of Ras through prenylation, the C-terminal addition of a lipid anchor. Small molecule inhibitors of farnesyl transferase (FTI), the enzyme most often responsible for prenylating Ras, showed clinical promise, but development of FTI such as tipifarnib has been stalled by uncertainty about their mechanism of action, since Ras appeared unimpeded in tipifarnib-treated samples. Interpretation was further complicated by the numerous proteins that may be farnesylated, as well as availability of an alternate prenylation pathway, geranylgeranylation. Initial observations of varied response by osteosarcoma cell lines to tipifarnib led us to evaluate the role of FTI in Ras signal alteration using osteosarcoma models.

We describe our novel, counter-intuitive finding that endogenous Ras activity increases in osteosarcoma when farnesyl transferase is inhibited either by tipifarnib or shRNA. In response to tipifarnib, variable growth arrest and/or cell death correlated with levels of activated ERK and p38 MAPK. Sensitivity to tipifarnib treatment was shown by growth inhibition and by an increase in subdiploid cell numbers; cells with such sensitivity had increased activation of ERK and p38 MAPK. Since Ras must be prenylated to be active, our findings suggest that geranylgeranylated N-Ras or K-Ras B interact differently with downstream effector proteins in sensitive osteosarcoma cells responding to tipifarnib, switching the balance from cell proliferation to growth inhibition.

Keywords

Osteosarcoma; Ras; farnesylation; Growth arrest

Introduction

There is great interest in disrupting cell signaling as a means of combating cancer, and one method is by blocking protein prenylation. Prenylation is a posttranslational process in which a lipid anchor is added to the C-terminus of proteins in order to allow membrane association (1–3). This lipid modification increases the hydrophobicity of the proteins and enhances interaction with membrane lipids and with other proteins (2,3).

There are two forms of prenylation: farnesylation and geranylgeranylation, mediated by the enzymes farnesyltransferase and geranylgeranyltransferase. Prenylated proteins contain a CAAX motif at their C-terminus: a cysteine (C), two aliphatic amino acids (A) (leucine, isoleucine, or valine), and a C-terminal serine, methionine, leucine, or glutamine (X) (4,5). This CAAX motif, along with the linker region at the C-terminus of proteins, determines which prenyl group is added to the protein (6).

Farnesyltransferase inhibitors (FTIs) are small molecules that inhibit prenylation of multiple proteins, including Ras, RhoB, Lamin A/C, and the centromere proteins (CENP-E and CENP-F) (1,7,8). Tipifarnib is an FTI that blocks farnesylation by competitively binding to the CAAX motif in proteins (4,9,10). In clinical trials, tipifarnib, when used alone or in combination with chemotherapy, has produced therapeutic responses in many cancers including acute myeloid leukemia (AML), breast cancer, head and neck squamous cell carcinoma, myelodysplastic syndrome (MDS), and myeloproliferative disorders (MPDs) (1). The intent of using FTIs therapeutically was to block activation of Ras which is oncogenic in many cancers, or is overactivated as a result of being downstream of oncogenic receptor tyrosine kinases (RTKs) as is often the case in breast carcinomas.

Ras proteins are small guanosine triphosphatases (GTPases) that regulate growth, differentiation, survival, and cell death (11–13). After Ras is prenylated, it associates with the cell membrane, functioning in signal transduction (5,14,15) and cycling between active (Ras-GTP) and inactive (Ras-GDP) states (11,12,16). There are four highly homologous Ras proteins, K-Ras A, K-Ras B, N-Ras, and H-Ras (9,12,13,16), all of which contain a CAAX motif in their C-terminus and can be farnesylated; K-Ras B and N-Ras can also be geranylgeranylated (17). Oncogenic Ras mutations are commonly found in cancer, and the specific mutated Ras species (if any) in a particular tumor is likely to determine whether FTI therapy will be useful (7). We chose to look at FTI effects in osteosarcoma because no oncogenic Ras mutations have been identified in osteosarcoma (18), perhaps because of the constitutive activity of receptor tyrosine kinases providing a similar effect on cell signaling (19).

Ras activates multiple pathways, and the best characterized are the mitogen-activated protein kinase (MAPK) cascades. The MAPK family includes extracellular signal-regulated kinase1/2 (ERK1/2), c-Jun N-terminal kinase (JNK), and p38. There are three evolutionarily conserved sequential kinases: MAPKK kinase (MAPKKK), MAPK kinase (MAPKK), and MAPK (20, 21), which are activated through phosphorylation by a small GTP-binding proteins such as Ras. There is overlap and crosstalk in these signaling cascades that regulate the balance of cell survival. Ras was originally thought to contribute only to proliferation and cell survival. However, Ras also has been shown to have roles in apoptosis, growth arrest, and senescence through activation of these same signaling molecules, depending on cellular context, the presence or absence of other regulatory molecules, and the persistence of the signal (12,16, 22–24).

We wanted to determine what effect FTI had on a disease which has identified no known mutations in Ras. This study is aimed to expand the knowledge of how FTI's exert their anti-neoplastic effects. The purpose of this study was to identify if FTI is effective in decreasing proliferation in cancer cells with wild type Ras. Increased Ras activity observed with tipifarnib treatment led us to determine the activation status of downstream effector molecules of Ras. ERK and p38 pathways were increased in osteosarcoma cells that underwent growth arrest in response to tipifarnib treatment. We therefore treated osteosarcoma cells with tipifarnib alone, with the geranylgeranyltransferase inhibitor GGTI-298 alone, or with combined tipifarnib and GGTI-298 to determine the prenylation status of N-Ras and K-Ras B. The results suggested

that when farnesylation is blocked with tipifarnib, N-Ras and K-Ras B are geranylgeranylated and their downstream signaling is altered, resulting in decreased cell survival and proliferation.

Materials and Methods

Cell culture and experimental reagents

Human osteosarcoma cell lines were maintained as follows: OS187, COL, CCH-OS-M, and CCH-OS-D cells were grown in DMEM 1X media (Invitrogen, Carlsbad, CA) with 10% fetal bovine serum (FBS) (HyClone, Logan, UT), 1% penicillin-streptomycin solution (Gemini Bio-Products, Woodland, CA), and 1% l-glutamine (Lonza, Walkersville, MD). COL, CCH-OS-M, and CCH-OS-D were given additional 1% insulin transferrin selenium-A solution (Invitrogen). SaOS2, LM7, and HOS were grown in MEM with 10% FBS, 1% penicillin-streptomycin, 1% l-glutamine, 1% MEM essential vitamins (Lonza), 1% sodium pyruvate (MP Biomedicals, Solon, OH), and 1% non-essential amino acids mixture (Cambrex Biosciences, East Rutherford, NJ). AML cell lines THP-1 and U937 (a kind gift from Dr. Patrick Zweidler-McKay, M.D. Anderson, Houston, TX) were maintained in RPMI high-glucose 1X media (Invitrogen), with 10% FBS and 1% penicillin-streptomycin. All cells were incubated in a humidified atmosphere at 37°C with 5% CO₂.

OS187, COL, SaOS2, LM7, and HOS have been described (19,25,26). CCH-OS-M and CCH-OS-D are primary osteosarcoma cell lines derived from patients at the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center. CCH-OS-D was obtained from a core needle biopsy of a proximal femur lesion in an 18-year-old boy who also presented with pulmonary metastases. CCH-OS-M was obtained from the malignant pleural effusion of a 15-year-old boy with recurrent pulmonary and pleural-based osteosarcoma 13 months after initial diagnosis of right proximal humerus osteosarcoma. Experiments were conducted between passages 8–13 for both cell lines.

Downstream Ras targets—OS187, COL, and SaOS2 were exposed to tipifarnib at the following concentrations for 24 hours: 0 μM, 0.01 μM, 0.1 μM, and 1 μM.

N- and K-Ras alternate prenylation—OS187, COL, and SaOS2 cells were treated with 1 μM tipifarnib, 4 μM GGTI-298, no drug, or both drugs for 24 hours.

Chemicals—Tipifarnib (Johnson & Johnson, Langhorne, PA) and GGTI-298 (CALBIOCHEM, San Diego, California) were dissolved in dimethyl sulfoxide as 10 mM stock solutions.

Cell viability assay

Osteosarcoma cells were plated in 6-well tissue culture plates at 100,000 cells/well. The following day, tipifarnib was added to achieve the following concentrations: 0 μM, 0.01 μM, 0.1 μM, and 1 μM, in triplicate. Cell nuclei were counted at 24, 48, 72, and 96 hours as follows: the medium was removed from the plates and the cells washed with 2 ml of PBS. 0.5 ml of 0.01 M HEPES/0.015 M MgCl₂ buffer was added, and cells were rocked for 5 minutes at room temperature to equilibrate. After equilibration, 50 μl of 0.132 M Bretol with 0.525 M glacial acetic acid was added, and the cells were rocked for 10 minutes at room temperature. A solution consisting of 3.5 ml of 0.9% NaCl and 0.5% formalin was added to fix the nuclear membranes, and 2 ml of the solution containing the nuclei was placed into an autosampler cup. Nuclei (5–25 μm) were counted by using an automated Vi-Cell Analyzer (Beckman Coulter, Fullerton, CA).

Invasion assay

Invasiveness was measured in a BD Matrigel invasion chamber, as described previously (27). Cells were treated with tipifarnib for 48 hours before plating, and drug was included in upper and lower chambers throughout the assay. Invasive cells were counted after 48 hours.

Cell cycle analysis

Cells were cultured with tipifarnib for 72 hours, then dead and live cells were collected and incubated overnight at 4°C with 0.005% propidium iodide, 0.1% Triton X100, diluted in PBS. Cells were analyzed on a FACS Calibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ).

Western blot analysis

Lysates were collected as follows: The medium was removed, plates were washed with cold PBS, and 1 mL of lysis buffer, as described previously (28) was added to each plate, and plates were incubated on ice for 35 minutes. Lysates were collected and centrifuged at 10,000 rpm for 10 minutes. Protein concentrations were determined by bicinchoninic acid (BCA) analysis (Thermo Scientific, Pittsburgh, PA). Whole cell lysates were separated by SDS-PAGE on a 12% or 15% polyacrylamide gel and transferred to nitrocellulose membrane according to standard techniques. Membranes were probed with use of the following antibodies: phospho-44/42 MAPK (9102), MEK1/2 (9122), phosphor-MEK 1/2 (9121S), phospho-p38 MAPK (9211), p38 MAPK (9212), MKK3 (9232), phosphor-MKK3/6 (9236), phosphor-MSK1 (9595), phosphor-ATF-2 (5112), and pan Ras (3965) (1:1000, all from Cell Signaling, Danvers, MA), MAPK/ERK (1:1000, Promega, Madison, WI, 17925803), Rap-1 (Millipore, Billerica, MA, 07-916), and Actin (1:1000, Sigma, A2066). Horseradish peroxidase-conjugated anti-rabbit IgG (1:4000, GE Healthcare) was used as secondary antibody for all antibodies listed above. Membranes were probed with use of HDJ-2 (Thermo Scientific, MS-225), K-Ras, and N-Ras (Santa Cruz, Santa Cruz, CA, sc-30 and sc-31). Horseradish peroxidase-labeled polyclonal anti-mouse Ig (1:5000, BD Biosciences, San Jose, CA, 554002) was used as secondary antibody for antibodies listed above. Chemiluminescent signal was detected by the Immobilon Western Blotting detection system (Millipore). Densitometry values are relative to actin and are representative of three experiments.

Ras activity

OS187, COL, and SaOS2 osteosarcoma cells were exposed to 0.01 μ M, 0.1 μ M, or 1 μ M tipifarnib or no drug. LM7, HOS, CCH-OS-M, and CCH-OS-D were treated with 0 μ M and 1 μ M. Lysates were made, and 1.5 mg/ml of protein was used for the Ras activity assay (Cell Biolabs Inc, San Diego, CA, STA-400). Immunoprecipitation and immunoblotting were conducted according to the manufacturer's directions.

Short hairpin RNA

Designing oligonucleotides—Two hairpin structures predicted to anneal to RNA of the β subunit of farnesyltransferase (FT β ; see Results for discussion of FT β) were designed with use of software provided by Invitrogen (<http://www.invitrogen.com/site/us/en/home.html>) and purchased from Sigma (St. Louis, MO). Lower case letters indicate sequence used for ligation only. 5' UTR, 1011 (top strand 5'-gatctGCGATTTGAAGGAGGATTTACGAATGAAATCCTCCTTCAAATCGCtttttC-3', bottom strand 5'-tcgagAAAAAAGCGATTTGAAGGAGGATTTTCATTCGTGAAATCCTCCTTCAAATCGCa-3') ORF, 1927 (top strand 5'-gatctGGTCCCAAGATGAGTTCTCGAAAGAACTCATCTTGGTGGGACCtttttC-3', bottom strand 5'-

tcgagAAAAAAGGTCCCACCAAGATGAGTTCTTTCGAGAACTCATCTTGGTGGGAC
Ca-3').

Annealing oligonucleotides—Annealing buffer: 100 mM NaCl and 50 mM HEPES (pH 7.4). 1 µl of 3 mg/ml stocks of top and bottom strand oligonucleotides were incubated with 48 µl of annealing buffer at the following temperatures for 4 minutes each: 94, 80, 75, 70, 65, 60, and 55°C. The mixture was incubated at room temperature for 1 hour and at 4°C for 20 minutes. To generate a retroviral expression system for short hairpin RNA (shRNA) expression, the MigR1 retroviral expression vector, coexpressing GFP as a selection marker, was manipulated to contain a U6 promoter upstream of the hairpin sequence; this vector is now termed MigU6. Hairpins were ligated into retroviral vector MigU6 by using a standard T4 ligation reaction.

Retroviral transduction—MigU6 empty vector, scrambled control, 1011, or 1922 were used to make replication-incompetent retrovirus, which was then used to infect osteosarcoma cells. To generate virus, 293T cells were seeded at 140,000 cells/well in a 6-well dish. After 24 hours, the following were incubated for 5 minutes: Tube A, 2 µg of MigU6 vectors, 2 µg of VSVG, 2 µg of PCGP (kind gifts from Dr. Patrick Zweidler-McKay), and 250 µl Opti-MEM (Invitrogen); tube B, 12 µl of lipofectamine (Invitrogen); and 250 µl Opti-MEM. A and B were combined and incubated at room temperature for 30 minutes; 500 µl of each complex was added to one well of 293T cells. After 8 hours, the complex was removed, fresh medium was added, and the plate was incubated at 32°C. Supernatant was collected at 24 hours and centrifuged at 2,500 RPM for 2 minutes. Next, 2.5 ml of viral supernatant and 8 µg/ml Polybrene (Sigma) were added to OS187 and SaOS2 cells. These plates were centrifuged at 2,500 RPM for 1 hour and then incubated at 32°C for 24 hours. Viral medium was removed and fresh medium added. Cells were sorted for GFP twice to generate a polyclonal population of transduced cells.

Lysates were generated and Ras activity was assayed as described above. Parallel samples of lysate were tested by Western blotting for FTβ (sc-137), and knockdown was confirmed by densitometric analysis (Image J Processing software, NIH).

Statistics

Significance was assessed by Student's t-test (Statistica Software) with an alpha error threshold of 0.05. All experiments were conducted at least three times.

Results

Tipifarnib decreases cell viability and causes cell cycle arrest in sensitive cell lines and decreases invasiveness in all cells

To determine the response of osteosarcoma cells to farnesyltransferase inhibition, three osteosarcoma cell lines were treated with increasing concentrations of tipifarnib. Cell viability was assayed by counting nuclei after chemical lysis of the plasma membrane to avoid counting dead or dying cells. There was a range of growth inhibition to tipifarnib among the various osteosarcoma cells. OS187 cells were the most sensitive, yielding reduced counts with as little as 0.001 µM tipifarnib (data not shown). COL also demonstrated a dose-dependent cell count reduction with tipifarnib. The reduced cell yields for OS187 and COL by 72 hours were significant, at 0.01 and 0.1 µM, with *P* values of 0.001 and 0.003 respectively, whereas SaOS2 did not show a significant reduction in cell yield in response to tipifarnib at 1 µM concentration after 96 hours of exposure (Fig. 1A). Variable responsiveness to tipifarnib has also been reported in numerous other cancer cell types, including AML and pancreatic cancer (29–31).

Phase-contrast light microscopic examination of OS187 cells after farnesyltransferase inhibition revealed enlarged, markedly “swollen” cells compared with untreated control cells after 24 hours (Fig. 1B, inset). We wanted to know if the reduced cell yields were due to growth arrest of viable cells and if so, whether the cells could recover, or whether the reduced yields were due to cell loss. To assess the duration of response to farnesyltransferase inhibition, OS187 cells were exposed to tipifarnib for 24, 48, or 72 hours and then washed and grown in fresh medium. After a total of 96 hours, cells were counted as above (Fig. 1B). No difference in cell yield was seen between cells treated with tipifarnib for only 24 hours and cells treated longer, regardless of washout duration.

We wished to know whether inhibition of farnesyltransferase would affect other hallmarks of cancer, especially invasion, a necessary step in metastasis. We therefore assessed the effect of FTI on invasion with use of Matrigel invasion assays. OS187 and COL cells showed decreased invasiveness that correlated with loss of cell viability data in Fig. 1A (data not shown). Of interest, SaOS2 cells, which had demonstrated little growth arrest with farnesyltransferase inhibition, showed decreased invasiveness, even at drug concentrations so low they had no effect on tumor cell growth (Fig. 1C).

Previous reports have shown that cells with wild-type Ras undergo growth arrest in the G2/M phase in response to FTI (32). To determine whether increased growth arrest occurs in osteosarcoma cell lines when farnesylation is inhibited, cells were treated with tipifarnib for 72 hours. Cell cycle analysis was conducted on detached and attached cells. OS187 cell numbers in G2/M increased by 72 hours, but no significant effect on cells in the G2/M cycle were seen in COL or SaOS2 cells (Fig. 1D). However, by 72 hours, dose-responsive increases in the number of sub-G1 cells were seen in OS187, COL, and SaOS2 cells, with the greatest increase in OS187, a moderate increase in COL, and a relatively small increase in SaOS2. There was no increase in G0/G1 or S-phase cells at any treatment or timepoint. This indicates a correlation between sub-G1 cells and growth arrest in cells that show reduced yield after FTI.

Blocking farnesyltransferase increases Ras activity

Several studies have examined the effects of FTIs on downstream effector molecules of Ras, with varied results: some investigators found decreased activation, whereas others detected no change in activation of effector proteins in response to inhibition of farnesyltransferase (23, 31,33), and therefore have been quick to disregard Ras as a protein that confers sensitivity to FTI.

To determine the effect of FTI on Ras activity in osteosarcoma cells, we used an assay that precipitates activated Ras through binding to the Ras binding domain (RBD) of Raf-1 conjugated to agarose beads. All osteosarcoma cells examined had low baseline levels of Ras activity when grown in standard conditions. We were surprised to find, however, that for all osteosarcoma cells, FTI caused up-regulation of Ras activity (Fig. 2A and B). Two AML cell lines, THP1 and U937, which have shown growth inhibition when treated with tipifarnib, were tested for activation of Ras in response to FTI (29, 30). THP-1 has an activating mutation at the 12 codon of N-Ras, and contains no known mutations in K- or H-Ras. U937 has no known mutations in any Ras proteins. Although U937 has no known mutations in Ras, U937 and THP-1 both have high endogenous expression of activated Ras, which is further increased when treated with 1 μ M tipifarnib for 24 hours (Fig. 2C).

Farnesyltransferase and geranylgeranyltransferase share a common α subunit but have separate β subunits. To verify that blocking farnesylation increases Ras, we used shRNA targeted to the β subunit of farnesyltransferase (FT β). We created two shRNAs: one targeted to the open reading frame and one to the 5' untranslated region of FT β . Both shRNAs were transduced into OS187 and SaOS2. Knockdown was quantified by Western blotting (Fig. 3A). Ras activation

was measured as above. Increased Ras activity was observed in the FT β shRNA–transduced cells. This is the first report, to our knowledge, that demonstrates increased activity of Ras in response to blocking farnesylation.

Tipifarnib treatment results in increased activation of ERK and p38 MAPK in sensitive cell lines

Inhibition of farnesyltransferase led to increased Ras activity, measured by Raf binding assays, but it was unclear whether this effect reflected an actual increase in Ras signaling. We assessed both ERK and p38. Activation of both pathways remained unchanged or decreased in SaOS2 cells (Fig. 4A). The endogenous level of activated ERK was low in COL, but it was increasingly activated in response to FTI. ERK and p38 were increasingly activated in OS187 and COL when farnesylation was blocked. Since p38 and ERK activation appeared to be associated with growth arrest after FTI, we examined the activation levels of proteins upstream and downstream of p38 and ERK in response to tipifarnib treatment. MKK3/6 and MEK 1/2 are kinases upstream of p38 and ERK respectively. Phosphorylated levels of these kinases were increased in OS187 and COL when treated with tipifarnib (Fig. 4B, Table 1). We also measured the response of ATF-2, a downstream effector protein of p38, and MSK-1, a downstream effector protein of ERK and p38. Both were increasingly phosphorylated in response to FTI in OS187 and COL densitometry values relative to actin shown in Table 1. Phosphorylated levels of MKK3/6, MSK1, and ATF-2 were low or undetectable in SaOS2, whereas phosphorylated MEK 1/2 levels remained unchanged. We concluded that osteosarcoma cells that undergo growth arrest and/or cell death in response to FTI have increased ERK and p38 activation as a part of that response.

N-Ras and K-Ras B are alternately prenylated with tipifarnib treatment

On the basis of the above work, we hypothesized that N-Ras and K-Ras B were geranylgeranylated when farnesyltransferase was inhibited. We therefore treated cells with an FTI (tipifarnib) alone, with a GGTI (GGTI-298) alone, or with a combination of both. Anti-Rap-1 staining verified that geranylgeranylation was blocked (34), and anti-HDJ-2 showed that farnesylation was blocked (35). A shift to a higher mobility band represents unprenylated forms of proteins. After validation that the targets were blocked, the prenylation status of the Ras isoforms was measured. For both pan-Ras and N-Ras, two bands were seen when farnesyltransferase only was blocked, but almost all of the protein was in the unprenylated form when both farnesylation and geranylgeranylation were blocked. The persistence of prenylated Ras when farnesylation was blocked (as demonstrated by the HDJ-2 mobility) suggests that some N-Ras could be geranylgeranylated when farnesylation was prevented (Fig. 5A). Although endogenous levels of K-Ras are difficult to detect in osteosarcoma cells using available antibodies, it is clear that there was no shift in mobility of K-Ras when only farnesyltransferase or geranylgeranyltransferase was inhibited (Fig. 5A). Blocking both enzymes did alter mobility, suggesting that either form of prenylation was readily available for K-Ras. These results indicated that N-Ras and K-Ras are both alternately prenylated when farnesylation is blocked.

To assess the impact on Ras activity of the inhibition of geranylgeranylation, parallel lysates were tested for Ras activation by Raf binding, as described above. Increased Ras activity was found only in cells in which farnesyltransferase was inhibited (Fig. 5B). There was no difference in Ras activity observed between untreated cells and cells in which geranylgeranyltransferase was inhibited, demonstrating that the increased Ras activation was a result of FTI specifically and not a general effect of prenylation inhibition.

Discussion

We demonstrated that farnesyltransferase inhibition by either tipifarnib or shRNA to FT β increases Ras activity. Although the nature of the relationship between increased Ras activation and cancer cell response remains to be determined, one intriguing possibility is that when farnesyltransferase is inhibited, the resulting increase in Ras activity contributes to growth arrest and/or cell death.

An increase of Ras activity was confirmed by the up-regulation of key downstream targets of Ras signaling in response to tipifarnib treatment. Specifically, we showed the effect of FTI on endogenous levels of Ras and MAPK proteins by using pharmacologic means to influence the prenylation status of Ras. We showed that decreasing farnesylated Ras increases the activation of ERK and p38 MAPK. The up-regulation of MAPK family members found in growth-arrested cells OS187 and COL, compared with the down-regulation and/or unchanged levels in cells without growth arrest (SaOS2), suggests that the functional increase in Ras signaling may be linked to the response seen in cells that undergo growth arrest.

Decreased proliferation, apoptosis, and senescence have all been reported responses to FTI (29,33,36,37). Although Ras activity normally is associated with growth factor responses, proliferation, survival, and an increase in many of the hallmark behaviors of cancer, there are circumstances in which Ras signaling can be associated with reduced survival (23,24,38–41). The outcome of Ras signaling depends upon the cellular context, the presence or absence of other regulatory molecules, and the persistence of the signal (16,24). Fibroblasts with wild-type p53 become susceptible to apoptosis when Ras is transiently expressed (16). Likewise, oncogenic activation of Ras in fibroblasts or primary human cells converts p53 into an inducer of senescence (40,41). SaOS2 is p53-null, which may render this cell line “resistant” to Ras-mediated cell death signals induced by FTI, due to lack of a key regulator of senescence and cell death. It may be that resistance to tipifarnib in many cancers may be due to a lack of key downstream proteins, such as p53 in SaOS2, which would account for senescence or cell death.

Many other proteins are farnesylated. Inhibition of farnesylation of these other proteins (such as RhoB, CENP-E, and CENP-F) may contribute to the decreased proliferation and growth arrest seen in OS187 and COL. However, increased Ras activity, in combination with increased phosphorylation of ERK and p38 MAPK, are key findings in responsive cells and likely contribute to the decreased proliferation and growth arrest. An increase in Ras activity in response to inhibition of farnesylation suggests that growth arrest and/or cell death may rely on a shift from farnesylated to geranylgeranylated Ras. The relationship between G2/M arrest and Ras signaling remains to be confirmed with experiments that are outside the scope of this report. The relationship between decreased invasiveness and increased Ras activity when farnesylation is inhibited is also unclear and may be due to the functional inhibition of H-Ras. H-Ras has been reported to increase invasiveness of various carcinomas (42,43). Raponi et al. found expression of *RASGRP1*, a guanine nucleotide exchange factor (GEF) that activates Ras, predicted sensitivity to tipifarnib treatment in AML (44). They report that *RASGRP1* normally activates N-Ras and H-Ras, but blockage of H-Ras by FTI may be responsible for some anti-tumor effects. The loss of H-Ras function due to FTI could account for the decreased invasiveness found in all three cell lines tested, especially SaOS2, which was otherwise not responsive to FTI after 96 hours of treatment with tipifarnib. Anti-sense to *AKT2* caused a loss of invasiveness in pancreatic carcinoma cells (45), and phosphorylated AKT was decreased in SaOS2 and OS187 in response to tipifarnib treatment (unpublished data). Negligible expression of H-Ras mRNA or protein was seen in any osteosarcoma cell line tested (unpublished data). However loss of H-Ras or loss of farnesylated N-Ras or K-Ras B might result in decreased phosphorylated AKT and therefore decreased invasiveness, although we recognize that other prenylated proteins also may contribute to this effect.

Our findings were consistent with previous studies which have reported that both an FTI and GGTI are required for inhibition of K-Ras processing (46). Tipifarnib treatment alone partially inhibited N-Ras prenylation, but the combination treatment inhibited prenylation of N-Ras to a greater extent. It is well accepted that Ras must be localized to a membrane to cause activation of downstream signaling proteins. Therefore, increased Ras activation resulting from inhibiting farnesylation suggests that Ras must be alternately prenylated, since unprenylated Ras would not remain membrane-associated and would not cause activation of ERK, p38, etc. These findings, along with the continued presence of prenylated Ras (as assessed by SDS-PAGE mobility) after either FTI or GGTI treatments alone, strongly suggest that N-Ras and K-Ras are alternately geranylgeranylated when farnesylation is inhibited.

The lack of mutations in Ras combined with the expression of proteins important in cell death or senescence suggests that some osteosarcoma patients might achieve clinical benefit from FTI. Since growth arrest was the predominant effect seen *in vitro*, we would not expect a clear loss of tumor volume by RECIST criteria from such treatment, but might see stable disease. Indeed, tumor shrinkage is uncommon with osteosarcoma therapy because tumors often calcify with treatment. *In vivo* studies are necessary to determine whether tipifarnib treatment induces stable disease in orthotopic xenograft models, which would lend support to pursuing clinical trials for this disease.

In conclusion, Ras activity is increased when farnesylation is inhibited. The combination of Ras activation and increased activation of MAPK family members in cells with decreased cell viability and growth arrest suggests that Ras is functionally important for response to tipifarnib treatment. Understanding how signaling pathways are altered in response to geranylgeranylated N-Ras and K-Ras B is of increasing importance and may lead to novel findings of how Ras signaling is able to switch from proliferative to antineoplastic.

Acknowledgments

Financial support: Jori Zemel Children's Bone Cancer Foundation, Rosalie B. Hite Fellowship, The University of Texas Graduate School of Biomedical Sciences and the National Cancer Institute (5 K08 CA118730).

References

1. Brunner TB, Hahn SM, Gupta AK, Muschel RJ, McKenna WG, Bernhard EJ. Farnesyltransferase Inhibitors: An Overview of the Results of Preclinical and Clinical Investigations. *Cancer Res* 2003 September 15;63(18):5656–5668.
2. Casey PJ. Biochemistry of protein prenylation. *J Lipid Res* 1992 December 1;33(12):1731–1740.
3. Winter-Vann AM, Casey PJ. Post-prenylation-processing enzymes as new targets in oncogenesis. *Nat Rev Cancer* 2005 May 1;5(5):405–412.
4. Adjei AA. Blocking Oncogenic Ras Signaling for Cancer Therapy. *J Natl Cancer Inst* 2001 July 18;93(14):1062–1074.
5. Zujewski J, Horak ID, Bol CJ, et al. Phase I and Pharmacokinetic Study of Farnesyl Protein Transferase Inhibitor R115777 in Advanced Cancer. *J Clin Oncol* 2000 February 14;18(4):927.
6. Maurer-Stroh S, Eisenhaber F. Refinement and prediction of protein prenylation motifs. *Genome Biol* 2005 January 1;6(6):R55.
7. Lancet JE, Karp JE. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. *Blood* 2003 December 1;102(12):3880–3889.
8. Pan J, Yeung S-CJ. Recent Advances in Understanding the Antineoplastic Mechanisms of Farnesyltransferase Inhibitors. *Cancer Res* 2005 October 15;65(20):9109–9112.
9. Sousa SF, Fernandes PA, Ramos MJ. Unraveling the mechanism of the farnesyltransferase enzyme. *J Biol Inorg Chem* 2005 January 1;10(1):3–10.

10. Reid TS, Beese LS. Crystal structures of the anticancer clinical candidates R115777 (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity. *Biochemistry* 2004 2004 June 8;43(22):6877–6884.
11. Khwaja A, Dockrell ME, Hendry BM, Sharpe CC. Prenylation is not necessary for endogenous Ras activation in non-malignant cells. *J Cell Biochem* 2006 2006 February 1;97(2):412–422.
12. Ashery U, Yizhar O, Rotblat B, Kloog Y. Nonconventional trafficking of Ras associated with Ras signal organization. *Traffic* 2006 2006 September 1;7(9):119–126.
13. Sherman, LS.; Ratner, N. Immunocytochemical Assay for Ras Activity. In: Press, A., editor. *Methods in Enzymology*. Academic Press; 2001. p. 348-355.
14. Basso AD, Kirschmeier P, Bishop WR. Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors. *J Lipid Res* 2006 2006 January 1;47(1):15–31.
15. Shaw NJ, Bishop NJ. Bisphosphonate treatment of bone disease. *Arch Dis Child* 2005 2005 May 1;90(5):494–499.
16. Berthiaume LG. Insider Information: How Palmitoylation of Ras Makes It a Signaling Double Agent. *Sci STKE* 2002 2002 October 1;2002(152):pe41.
17. Whyte DB, Kirschmeier P, Hockenberry TN, et al. K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors. *J Biol Chem* 1997 1997 May 30;272(22):14459–14464.
18. Antillon-Klussman F, Garcia-Delgado M, Villa-Elizaga I, Sierrasesumaga L. Mutational activation of ras genes is absent in pediatric osteosarcoma. *Cancer Genet Cytogenet* 1995 1995 January 1;79(1):49–53.
19. Hughes DP, Thomas DG, Giordano TJ, McDonagh KT, Baker LH. Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition. *Pediatr Blood Cancer* 2006 2006 May 1;46(5):614–623.
20. Roux PP, Blenis J. ERK and p38 MAPK-Activated Protein Kinases: a Family of Protein Kinases with Diverse Biological Functions. *Microbiol Mol Biol Rev* 2004 2004 June 1;68(2):320–344.
21. Junttila MR, Li S-P, Westermarck J. Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. *FASEB J* 2008 2008 April 1;22(4):954–965.
22. Bivona TG, Quatela SE, Bodemann BO, et al. PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis. *Mol Cell* 2006 2006 February 17;21(4):481–493.
23. Ninomiya Y, Kato K, Takahashi A, et al. K-Ras and H-Ras Activation Promote Distinct Consequences on Endometrial Cell Survival. *Cancer Res* 2004 2004 April 15;64(8):2759–2765.
24. Yang R, Piperdi S, Gorlick R. Activation of the RAF/Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase/Extracellular Signal-Regulated Kinase Pathway Mediates Apoptosis Induced by Chelerythrine in Osteosarcoma. *Clin Cancer Res* 2008 2008 October 15;14(20):6396–6404.
25. Lisle JW, Choi JY, Horton JA, Allen MJ, Damron TA. Metastatic osteosarcoma gene expression differs in vitro and in vivo. *Clin Orthop Relat Res* 2008 2008 September 1;466(9):2071–2080.
26. Santala P, Larjava H, Nissinen L, Riikonen T, Maatta A, Heino J. Suppressed collagen gene expression and induction of alpha 2 beta 1 integrin-type collagen receptor in tumorigenic derivatives of human osteogenic sarcoma (HOS) cell line. *J Biol Chem* 1994 1994 January 14;269(2):1276–1283.
27. Zhang P, Yang Y, Zweidler-McKay PA, Hughes DPM. Critical Role of Notch Signaling in Osteosarcoma Invasion and Metastasis. *Clin Cancer Res* 2008 2008 May 15;14(10):2962–2969.
28. Tibes R, Qiu Y, Lu Y, et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. *Mol Cancer Ther* 2006 2006 October 1;5(10):2512–2521.
29. Raponi M, Belly RT, Karp JE, Lancet JE, Atkins D, Wang Y. Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia. *BMC Cancer* 2004 2004 August 25;4:56.
30. Yanamandra N, Colaco NM, Parquet NA, et al. Tipifarnib and Bortezomib Are Synergistic and Overcome Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma and Acute Myeloid Leukemia. *Clin Cancer Res* 2006 2006 January 15;12(2):591–599.

31. Venkatasubbarao K, Choudary A, Freeman JW. Farnesyl Transferase Inhibitor (R115777)-Induced Inhibition of STAT3(Tyr705) Phosphorylation in Human Pancreatic Cancer Cell Lines Require Extracellular Signal-Regulated Kinases. *Cancer Res* 2005 2005 April 1;65(7):2861–2871.
32. Ashar HR, James L, Gray K, et al. Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the Microtubules. *J Biol Chem* 2000 2000 September 22;275(39):30451–30457.
33. Caraglia M, Marra M, Leonetti C, et al. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. *J Cell Physiol* 2007 2007 May 1;211(2):533–543.
34. Efuet ET, Keyomarsi K. Farnesyl and Geranylgeranyl Transferase Inhibitors Induce G1 Arrest by Targeting the Proteasome. *Cancer Res* 2006 2006 January 15;66(2):1040–1051.
35. Davis AR, Alevy YG, Chellaiah A, Quinn MT, Mohanakumar T. Characterization of HDJ-2, a human 40 kD heat shock protein. *Int J Biochem Cell Biol* 1998 1998 November 1;30(11):1203–1221.
36. Brassard DL, English JM, Malkowski M, Kirschmeier P, Nagabhushan TL, Bishop WR. Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras. *Exp Cell Res* 2002 2002 February 15;273(2):138–146.
37. Wang C-C, Liao Y-P, Mischel PS, Iwamoto KS, Cacalano NA, McBride WH. HDJ-2 as a Target for Radiosensitization of Glioblastoma Multiforme Cells by the Farnesyltransferase Inhibitor R115777 and the Role of the p53/p21 Pathway. *Cancer Res* 2006 2006 July 1;66(13):6756–6762.
38. Shao J, Sheng H, DuBois RN, Beauchamp RD. Oncogenic Ras-mediated Cell Growth Arrest and Apoptosis are Associated with Increased Ubiquitin-dependent Cyclin D1 Degradation. *J Biol Chem* 2000 2000 July 21;275(30):22916–22924.
39. Vos MD, Ellis CA, Elam C, Ulku AS, Taylor BJ, Clark GJ. RASSF2 Is a Novel K-Ras-specific Effector and Potential Tumor Suppressor. *J Biol Chem* 2003 2003 July 18;278(30):28045–28051.
40. Castro ME, del Valle Guijarr M, Moneo V, Carnero A. Cellular senescence induced by p53-ras cooperation is independent of p21waf1 in murine embryo fibroblasts. *J Cell Biochem* 2004 2004 June 1;92(3):514–524.
41. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. *Cell* 1997 1997 March 7;88(5):593–602.
42. Gotzmann J, Huber H, Thallinger C, et al. Hepatocytes convert to a fibroblastoid phenotype through the cooperation of TGF- β 1 and Ha-Ras: steps towards invasiveness. *J Cell Sci* 2002 2002 March 15;115(6):1189–1202.
43. Zhang Z, Yao R, Li J, et al. Induction of Invasive Mouse Skin Carcinomas in Transgenic Mice with Mutations in Both H-ras and p53. *Mol Cancer Res* 2005 2005 October 1;3(10):563–574.
44. Raponi M, Lancet JE, Fan H, et al. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. *Blood* 2008 2008 March 1;111(5):2589–2596.
45. Cheng JQ, Ruggeri B, Klein WM, et al. Amplification of AKT2 in human pancreatic cancer cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. *PNAS* 1996 1996 April 16;93(8):3636–3641.
46. Sun J, Qian Y, Hamilton AD, Sebt SM. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. *Oncogene* 1998 1998 March 1;16(11):1467–1473.

Figure 1A-1C

Figure 1D

Figure 1.

Differential susceptibility to tipifarnib treatment. **A**, Cell viability (yield) analysis of sensitive, intermediate, and resistant osteosarcoma cells with increasing tipifarnib concentrations by Coulter counter. **B**, OS187 cells were treated with tipifarnib for 24, 48, or 72 hours. The medium was removed and replaced with fresh medium containing no drug. Cells counts at 96 hours were compared with those of untreated cells and with those of cells treated for 96 hours. Inset shows phase-contrast light micrographs of OS187 cells cultured either in standard conditions or in 1 μM tipifarnib. Scale bar represents 0.1 mm. **C**, SaOS2 cells were treated with tipifarnib for 48 hours and then assayed for invasive ability. **D**, Cell cycle analysis conducted by flow cytometry: cells were incubated with tipifarnib at the indicated concentrations for 72 hours. (* P value = 0.05; ** P value $\leq$ 0.01). Data are representative of 3 or more experiments.

Figure 2.

Ras activity increases with tipifarnib treatment. **A**, Ras activity assay in OS187, COL, and SaOS2. Cells were treated with 0, 0.01, 0.1, or 1 μ M tipifarnib for 24 hours, lysates were collected, activated Ras was precipitated with Raf-1 RBD, and activated Ras was measured by immunoblot. Immunoblot of HDJ-2 is a control assessing farnesyl transferase inhibition. U, unfarnesylated, F, farnesylated. **B**, Cells from four additional osteosarcoma cell lines treated with 1 μ M tipifarnib and compared with untreated cells. Lysates were assayed as in **A** above. **C**, Two AML cell lines were subjected to the same parameters as in **B**, above. Densitometric analysis shows relative increases of activated Ras with tipifarnib treatment. Data are representative of 3 or more experiments.

Figure 3.

Ras activity is increased with inhibition of FT β in OS187 and SaOS2 cells. Retrovirally encoded shRNA specific for the beta subunit of farnesyl transferase (FT β) was transduced into OS187 and SaOS2. **A**, Western blot shows knockdown of FT β . **B**, Ras activity assay shows increased Ras activity with knockdown of FT β . Densitometric analysis demonstrates relative decrease in FT β expression (**A**) and relative increase in Ras activity (**B**). U6, empty vector; sh, scrambled control hairpin; 1011 and 1922, two distinct shRNAs specific for the beta subunit of farnesyl transferase. Analysis was performed as in Figure 2.

Figure 4.

Downstream effectors of Ras are increased in sensitive osteosarcoma cell lines. **A**, Phosphorylated and/or total levels of Ras downstream effectors in response to tipifarnib treatment. Cells were treated with 0, 0.01, 0.1, or 1 μ M tipifarnib for 24 hours. Numbers above each blot show the proportionate change in densitometry relative to actin compared with the untreated cell sample. **B**, Signaling molecules upstream and downstream of p38 and ERK are increased with farnesyltransferase inhibition. Cells were treated with 1 μ M tipifarnib for 24 hours and lysates assayed by Western blotting. Analysis was performed as in Figure 2.

Figure 5.

K-Ras and N-Ras are alternately prenylated with tipifarnib treatment. Cells were treated with 1 μ M tipifarnib, 4 μ M GGTI-298, alone or in combination, for 24 hours. **A**, Cell lysates were assayed by Western blotting. Prenylated (P) and unprenylated (UP), farnesylated (F) and unfarnesylated (UF), and geranylgeranylated (G) and ungeranylgeranylated (UG). **B**, Ras activity assay was measured on the same samples; assay was performed as in Fig. 2. Analysis was performed as in Figure 2.

Table 1

Densitometry from Figure 4B western blot. Analysis was performed as stated in Figure 4.

	SaOS2	COL	OS187
p-MKK3/6	0.52	1.46	1.15
Total MKK3/6	0.92	1.49	0.91
p-MEK1/2	1.05	2.77	1.40
Total MEK	1.05	1.60	0.85
p-MSK1	0.78	37.12	11.09
P-ATF-2	1.76	2.30	2.76